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Introduction
BCG, or bacille Calmette-Guérin, is a vaccine for 
tuberculosis (TB) disease. Many foreign-born 
persons have been BCG-vaccinated. BCG is used 
in many countries with a high prevalence of TB 
to prevent childhood tuberculous meningitis 
and miliary disease. However, BCG is not 
generally recommended for use in the United 
States because of the low risk of infection with 
Mycobacterium tuberculosis (M. tuberculosis), 
the variable effectiveness of the vaccine against 
adult pulmonary TB, and the vaccine’s potential 
interference with tuberculin skin test reactivity. 
The BCG vaccine should be considered only for 
very select persons who meet specific criteria  
and in consultation with a TB expert.
Recommendations
Children. BCG vaccination should only be 
considered for children who have a negative 
tuberculin skin test (TST) and who are 
continually exposed, and cannot be separated 
from, adults who
 • Are untreated or ineffectively treated for TB 
disease (if the child cannot be given long-
term treatment for infection); or 
 • Have TB caused by strains resistant to 
isoniazid and rifampin.
Health Care Workers. BCG vaccination of 
health care workers should be considered on an 
individual basis in settings in which
A high percentage of TB patients are infected 
with M. tuberculosis strains resistant to both 
isoniazid and rifampin; 
 • There is ongoing transmission of such drug-
resistant M. tuberculosis strains to health care 
workers and subsequent infection is likely; or 
 • Comprehensive TB infection-control 
precautions have been implemented, but 
have not been successful.
Health care workers considered for BCG 
vaccination should be counseled regarding the 
risks and benefits associated with both BCG 
vaccination and treatment of latent TB infection 
(LTBI).
Contraindications
Immunosuppression. BCG vaccination 
should not be given to persons who are 
immunosuppressed (e.g., persons who are 
HIV infected) or who are likely to become 
immunocompromised (e.g., persons who are 
candidates for organ transplant).
Pregnancy. BCG vaccination should not be  
given during pregnancy. Even though no harmful 
effects of BCG vaccination on the fetus have been 
observed, further studies are needed to prove 
its safety.
Testing for TB in BCG-Vaccinated 
Persons
The TST and TB blood tests to detect TB infection 
are not contraindicated for persons who have been 
vaccinated with BCG.
TST. BCG vaccination may cause a false-positive 
reaction to the TST, which may complicate 
decisions about prescribing treatment. The 
presence or size of a TST reaction in persons who 
have been vaccinated with BCG does not predict 
whether BCG will provide any protection against 
TB disease. Furthermore, the size of a TST reaction 
in a BCG-vaccinated person is not a factor in 
determining whether the reaction is caused by 
LTBI or the prior BCG vaccination. (See below for 
specific guidance on skin test results.)
TB Blood Tests. Blood tests to detect TB infection, 
unlike the TST, are not affected by prior BCG 
vaccination and are less likely to give a false-
positive result.
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Treatment for LTBI in BCG-
Vaccinated Persons
Treatment of LTBI substantially reduces the risk 
that TB infection will progress to disease. Careful 
assessment to rule out the possibility of TB 
disease is necessary before treatment for LTBI is 
started. Evaluation of TST reactions in persons 
vaccinated with BCG should be interpreted using 
the same criteria for those not BCG-vaccinated. 
Persons in the following high-risk groups should 
be given treatment for LTBI if their reaction to the 
TST is at least 5 mm of induration or they have a 
positive result using a TB blood test:
 • HIV-infected persons 
 • Recent contacts to a TB case 
 • Persons with fibrotic changes on chest 
radiograph consistent with old TB 
 • Patients with organ transplants 
 • Persons who are immunosuppressed for 
other reasons (e.g., taking the equivalent of 
>15 mg/day of prednisone for 1 month or 
longer, taking TNF-α antagonists)
In addition, persons in the following high-risk 
groups should be considered for treatment of 
LTBI if their reaction to the TST is at least 10 mm of 
induration or they have a positive result using a 
TB blood test:
 • Recent arrivals (less than 5 years) from high-
prevalence countries 
 • Injection drug users 
 • Residents and employees of high-risk 
congregate settings (e.g., correctional 
facilities, nursing homes, homeless shelters, 
hospitals, and other health care facilities) 
 • Mycobacteriology laboratory personnel 
 • Persons with clinical conditions that place 
them at high-risk for developing TB disease 
(e.g., diabetes)
 • Children less than 4 years of age, or children 
and adolescents exposed to adults in high-
risk categories
Persons with no known risk factors for TB may be 
considered for treatment of LTBI if their reaction to 
the tuberculin test is at least 15 mm of induration 
or they have a positive result using a TB blood 
test. Targeted skin testing programs should only 
be conducted among high-risk groups. All testing 
activities should be accompanied by a plan for 
follow-up care for persons with TB infection or 
disease.
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